Patents Examined by Michael J Schmitt
  • Combination comprising palmitoylethanolamide (PEA) and lycopene for use in the treatment of inflammatory diseases
    Patent number: 10987323
    Abstract: The object of the present invention is the combination of palmitoylethanolamide (PEA) and lycopene, and/or pharmaceutically acceptable salts and/or derivatives thereof, the pharmaceutical formulations comprising the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, optionally together with at least one pharmacologically acceptable excipient, and the use of the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, and of the formulations comprising such a combination, in the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: April 27, 2021
    Assignee: ALI RESEARCH SRLS
    Inventors: Raffaele Migliaccio, Antonella Sardei, Carmela Migliaccio
  • Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity
    Patent number: 10975048
    Abstract: The invention belongs to the field of biomedical research involving the 1,3,4-selenyldiazo derivatives that have cell protective activity. Because there are not so many heterocyclic selenium compounds, we synthesized a new type of selenium analog of BPTES. As the isoacceptor of BPTES, the compounds have antitumor activity, anti-oxidation and cell protection function. Currently many drugs contain the thiodiazo motif, so synthesis of selenyldiazo functional group could further optimize these drugs and are important in new drug development and application.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: April 13, 2021
    Inventors: Benfang Helen Ruan, Jennifer Jin Ruan
  • Bis-heteroaryl derivatives as modulators of protein aggregation
    Patent number: 10975066
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking, Adrian Hall, Malcolm Maccoss
  • Ketamine formulation for subcutaneous injection
    Patent number: 10973780
    Abstract: Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 13, 2021
    Assignee: Bexson Biomedical, Inc.
    Inventors: Jeffrey Becker, Gregg Peterson, Jason Wallach
  • Ataxia therapeutic compositions and methods
    Patent number: 10973812
    Abstract: A method for treating a subject having, or at risk of having, ataxia, generally includes administering to the subject an amount of a composition comprising a cholecystokinin receptor (Cck1R) agonist effective to ameliorate at least one symptom or clinical sign of ataxia.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 13, 2021
    Assignees: Regents of the University of Minnesota, Baylor College of Medicine
    Inventors: Harry T. Orr, Emily A. L. Wozniak, Huda Y. Zoghbi
  • Pharmaceutical formulation
    Patent number: 10973821
    Abstract: A pharmaceutical composition suitable for oral administration comprising particles of 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- oxoacetamideis provided. Also provided is a pharmaceutical composition suitable for parenteral administration wherein the composition comprises 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide. The compositions are useful in the treatment of fungal infection in a subject in need thereof.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: April 13, 2021
    Assignee: F2G LIMITED
    Inventors: Derek Law, Graham Edward Morris Sibley
  • Eco-friendly non-aqueous antimicrobial composition comprising hinokitiol with 1,3-propanediol and/or sorbitan caprylate
    Patent number: 10973228
    Abstract: [Problem] The object is to obtain cosmetics which do not show primary skin irritation or sensitization, and do not impart any unpleasant sensation such as sharp pain or prickly sensation when employed as a cosmetic, with the lowest possible inclusion of preservative/fungicide. [Solution] Antimicrobial low-irritant cosmetics characterized in that they contain one or two or more tropolone derivative(s) and one or two or more polyhydric alcohol(s) in quantities which have an anti-microbial effect and low skin irritancy.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: April 13, 2021
    Assignee: ISP INVESTMENTS LLC
    Inventors: Nadia Konate, Andrea Wingenfeld
  • CCL5 inhibitors
    Patent number: 10940132
    Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: March 9, 2021
    Assignee: AFECTA PHARMACEUTICALS, INC.
    Inventor: Bruce Kovacs
  • Methods of providing solriamfetol therapy to subjects with impaired renal function
    Patent number: 10940133
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 9, 2021
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Katayoun Zomorodi
  • Modulators of DUX4 for regulation of muscle function
    Patent number: 10933068
    Abstract: Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 2, 2021
    Assignee: Sonic Master Limited
    Inventors: Amanda Rickard, Anabel De La Garza, Uli Schmidt, Alexander Kiselyov
  • Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
    Patent number: 10933045
    Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 2, 2021
    Assignee: LACHESIS BIOSCIENCES LIMITED
    Inventor: Timothy Matthias Morgan
  • SHP2 phosphatase inhibitors and methods of use thereof
    Patent number: 10934302
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 2, 2021
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
    Patent number: 10899780
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: January 26, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • Platinum complex, its preparation and therapeutic use
    Patent number: 10899781
    Abstract: A platinum complex includes a structure of Formula (I). A method for treating a subject suffering from cancer includes a step of administering an effective amount of the platinum complex to the subject. A method for inhibiting the growth of cancer cells includes the step of contacting a population of cancer cells with an effective amount of the platinum complex. The platinum complexes are particularly suitable for treatment of cancer through, in particular, photodynamic therapy.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 26, 2021
    Assignee: City University of Hong Kong
    Inventors: Guangyu Zhu, Zhigang Wang, Zoufeng Xu
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10894774
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 19, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10882827
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: January 5, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Christopher J Molineaux, Thomas B Neff, Volkmar Guenzler-Pukall, Robert C Stephenson, Todd W Seeley, Ingrid Langsetmo Parobok
  • Predictive markers for polyamine inhibitor cancer therapies
    Patent number: 10845366
    Abstract: The present invention relates to therapeutic methods and medical uses comprising the identification and use of cancer marker surrogates for increased polyamine expression. These markers may be used to identify patients who may be treated for diseases and disorders that are susceptible to polyamine synthesis inhibitors, and they can also be used to monitor therapeutic responses when such agents are used.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: November 24, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Eugene Gerner, Edwin Paz, Bonnie Lafleur, Jenaro Garcia-Huidobro
  • Pharmaceutical composition for modified release
    Patent number: 10842780
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: November 24, 2020
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Yuuki Takaishi, Yutaka Takahashi, Takashi Nishizato, Daisuke Murayama, Emiko Murayama, Soichiro Nakamura, Kazuhiro Sako
  • Method for predicting a treatment response to a CRHR1 antagonist and/or a Vantagonist in a patient with depressive and/or anxiety symptoms
    Patent number: 10837062
    Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: November 17, 2020
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Florian Holsboer, Bertram Müller-Myhsok